Lacklustre Performance Is Driving Heron Therapeutics, Inc.’s (NASDAQ:HRTX) 26% Price Drop
The Heron Therapeutics, Inc. (NASDAQ:HRTX) share price has softened a substantial 26% over the previous 30 days, handing back much of the gains the stock has made lately. Instead of being rewarded, shareholders who have already held through the last twelve months are now sitting on a 32% share price drop.
Following the heavy fall in price, Heron Therapeutics may be sending very bullish signals at the moment with its price-to-sales (or “P/S”) ratio of 1.9x, since almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 8.8x and even P/S higher than 51x are not unusual. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S….
